Planisware expands into Belgium to support the sustained growth of its business in the Benelux region Paris, France, June 5, 2025 – Planisware, a leading B2B provider of SaaS in the rapidly growing Project Economy market, continues its international expansion with the opening of a new office in Belgium. Planisware has been present in the Benelux region for several years, through projects carried out for leading clients such as Galapagos, KLM, Philips, and Engie, and is now consolidating its position in this strategic, fast-growing market. In particular, the Group has seen a sharp increase in its business in this market, with revenue doubling over the last four years, testifying to the relevance of its expertise and the confidence of its customers. This new location is primarily intended to strengthen proximity to Planisware’s customers...

Geneva, Switzerland, June 5, 2025 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail Kalinichev, Head of Translational Science at Addex will describe the progress seen to date with the Addex GABAB PAM cough program, including antitussive data from in vivo models. Addex lead drug candidate is ready to start IND enabling studies. Details of the Presentation Date:               Saturday, June 7, 2025Time:              11:20 am ESTTitle: ...

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David Veitch, Basilea’s Chief Executive Officer, stated: “This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients...

SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform, as well as a digital insurance brokerage provider in Greater Southeast Asia, today announced a strategic partnership with Rizal Commercial Banking Corporation (“RCBC”), a trusted leader in Philippine banking known for its customer-focused innovation and inclusive financial services, through its card servicing entity, RCBC Bankard Services Corporation (“RCBC Credit Cards”). Through this collaboration, MoneyHero will integrate RCBC’s full suite of rewards, lifestyle, travel, and premium credit card products into its digital platform, enabling Filipinos to seamlessly discover, compare, and apply for cards that suit their personal financial needs. This partnership...

NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants. Each Warrant will expire two and one-half (2.5) years from the issuance, will be immediately exercisable upon issuance at an initial exercise price of $7.3575 per share, subject to adjustment on the First Reset Date and the Second Reset Date (as defined in the warrants) and subject to a floor price therein....

LAS VEGAS, June 04, 2025 (GLOBE NEWSWIRE) — BitMine Immersion Technologies, Inc. (“BitMine” and the “Company”) (NYSE American: BMNR), a technology company focused on the accumulation of bitcoin for long-term investment, whether acquired by their bitcoin mining operations or from the proceeds of capital raising transactions, today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $8.00 per share, for gross proceeds of $18 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 337,500 shares of common stock to cover over-allotments, if any. The offering is expected to close on June 6, 2025 subject to satisfaction of customary closing conditions. The...

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) — BWR Exploration Inc. (BWR.V TSX.V) (“BWR”), is pleased to announce that as per the previously announced Bridge Financing regarding a proposed business combination with Electro Metals and Mining Inc. (“Electro”), a federally registered private company, both companies have raised $240,000, surpassing the minimum aggregate amount needed as a condition of the proposed business combination as announced on December 27, 2024. Private Placements It was a condition of completion of the Transaction (as described herein) that each of each of BWR and Electro complete a unit financing to raise a minimum of $220,000 up to a combined $300,000 for immediate use for near term commitments and to advance the Transaction (the “Bridge Financings”). BWR and Electro have raised an aggregate of $240,000. BWR Bridge...

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million REYKJAVIK, ICELAND (June 4, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has completed a private placement of the equivalent of 7,500,000 shares in Swedish Depository Receipts (“SDRs”) and...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”). The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced...